Background There is a major unmet need for effective treatments in patients with squamous
cell carcinoma of the lung. LUX-Lung 8 compared afatinib (an irreversible ErbB family …

Summary Background Afatinib, an irreversible ErbB-family blocker, has shown preclinical
activity when tested in EGFR mutant models with mutations that confer resistance to EGFR …

Background Afatinib has demonstrated clinical benefit in patients with non-small-cell lung
cancer progressing after treatment with erlotinib/gefitinib. This phase III trial prospectively …

Abstract Purpose This Phase I study determined the maximum-tolerated dose (MTD) of
afatinib (Afatinib is an investigational compound and its safety and efficacy have not yet …

Background Afatinib is an irreversible ErbB-family blocker with preclinical activity in non-
small-cell lung cancer (NSCLC) with EGFR mutations. We aimed to assess the efficacy of …

Abstract Afatinib (Gilotrif™, Giotrif®) is an orally administered, irreversible inhibitor of the
ErbB family of tyrosine kinases. Afatinib downregulates ErbB signalling by covalently …

Purpose We tried to evaluate whether there are any specific features in treatment outcomes
of firstline afatinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small …

Background Patient-reported symptom and health-related quality of life (HRQoL) benefit of
afatinib, a novel, irreversible, ErbB Family Blocker, was investigated in a double-blind …

Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …

Background Afatinib is an oral, irreversible ErbB family blocker that has shown activity in
epidermal growth factor receptor (EGFR)-mutated lung cancer. We hypothesized that the …